Drug Evaluation, Preclinical

• 

  Subject Areas on Research

  • (Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen. 
  • A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. 
  • A Screen for Extracellular Signal-Regulated Kinase-Primed Glycogen Synthase Kinase 3 Substrates Identifies the p53 Inhibitor iASPP. 
  • A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease. 
  • A biomimetic Schlemm's canal inner wall: A model to study outflow physiology, glaucoma pathology and high-throughput drug screening. 
  • A catalytic antioxidant (AEOL 10150) attenuates expression of inflammatory genes in stroke. 
  • A comprehensive evaluation of catalase-like activity of different classes of redox-active therapeutics. 
  • A high throughput screen identifies Nefopam as targeting cell proliferation in β-catenin driven neoplastic and reactive fibroproliferative disorders. 
  • A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. 
  • A novel approach for characterizing protein ligand complexes: molecular basis for specificity of small-molecule Bcl-2 inhibitors. 
  • A novel human endometrial epithelial cell line for modeling gynecological diseases and for drug screening. 
  • A systematic review of methodology applied during preclinical anesthetic neurotoxicity studies: important issues and lessons relevant to the design of future clinical research. 
  • A tarantula-venom peptide antagonizes the TRPA1 nociceptor ion channel by binding to the S1-S4 gating domain. 
  • ALSUntangled 44: curcumin. 
  • ALSUntangled No. 29: MitoQ. 
  • ALSUntangled No. 34: GM604. 
  • Activation of cyclophosphamide for in vitro testing of cell sensitivity. 
  • Agonists of G-Protein-Coupled Odorant Receptors Are Predicted from Chemical Features. 
  • An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. 
  • An in vitro assay procedure to test chemotherapeutic drugs on cells from human solid tumors. 
  • An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets. 
  • An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral. 
  • Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. 
  • Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. 
  • Anesthetic neuroprotection: antecedents and an appraisal of preclinical and clinical data quality. 
  • Anti-AIDS agents 87. New bio-isosteric dicamphanoyl-dihydropyranochromone (DCP) and dicamphanoyl-khellactone (DCK) analogues with potent anti-HIV activity. 
  • Anti-inflammatory effects of progesterone in lipopolysaccharide-stimulated BV-2 microglia. 
  • Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. 
  • Antithrombotic effect of ticlopidine in an experimental model of retinal vein occlusion. 
  • Antithrombotic potencies of enoxaparin in microvascular surgery: influence of dose and administration methods on patency rate of crushed arterial anastomoses. 
  • Antitumor Agents, CLI. Bis(helenalinyl)Glutarate and Bis(isoalantodiol-B)-Glutarate, Potent Inhibitors of Human DNA Topoisomerase II 
  • Anxiolytic effects of nicotine in zebrafish. 
  • Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. 
  • Aptamers: an emerging class of therapeutics. 
  • Attenuation of alcohol intake by extract of Hypericum perforatum (St. John's Wort) in two different strains of alcohol-preferring rats. 
  • Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies. 
  • BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT. 
  • Bayesian Multi-Plate High-Throughput Screening of Compounds. 
  • Bosentan, an endothelin antagonist, augments hepatic graft function by reducing graft circulatory impairment following ischemia/reperfusion injury. 
  • CAP--advancing the evaluation of preclinical Alzheimer disease treatments. 
  • COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. 
  • Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. 
  • Characterizing sources of variability in zebrafish embryo screening protocols. 
  • Chemical interrogation of the malaria kinome. 
  • Chi-square test for R x C contingency tables with clustered data. 
  • Chromatographic analysis and decomposition product characterization of compound SR16157 (NSC 732011). 
  • Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. 
  • Coenzyme Q10 protects ischemic myocardium in an open-chest swine model. 
  • Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials. 
  • Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. 
  • Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research. 
  • Comparative study of machine-learning and chemometric tools for analysis of in-vivo high-throughput screening data. 
  • Comparison of various hemoglobin polyoxyethylene conjugate solutions as resuscitative fluids after hemorrhagic shock. 
  • Computational design, synthesis and biological evaluation of para-quinone-based inhibitors for redox regulation of the dual-specificity phosphatase Cdc25B. 
  • Computationally guided high-throughput design of self-assembling drug nanoparticles. 
  • Conformation guides molecular efficacy in docking screens of activated β-2 adrenergic G protein coupled receptor. 
  • Conformational considerations in the design of dual antagonists of platelet-activating factor (PAF) and histamine. 
  • Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. 
  • Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. 
  • Controlled release of ethacrynic acid from poly(lactide-co-glycolide) films for glaucoma treatment. 
  • Correlation of intralesional in vivo chemotherapy of line 10 hepatoma with in vitro drug sensitivity. 
  • Cost of innovation in the pharmaceutical industry. 
  • Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. 
  • Cytokine-Mediated Tissue Injury in Non-human Primate Models of Viral Infections. 
  • Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgetics. 
  • Development of a fluorescent ligand-binding assay using the AcroWell filter plate. 
  • Development of a high-throughput screening assay for inhibitors of small ubiquitin-like modifier proteases. 
  • Development of a novel screen for protease inhibitors. 
  • Dihydroquinazolinone inhibitors of proliferation of blood and liver stage malaria parasites. 
  • Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing. 
  • Discovery of Dual-Stage Malaria Inhibitors with New Targets. 
  • Discovery of geranylgeranyltransferase-I inhibitors with novel scaffolds by the means of quantitative structure-activity relationship modeling, virtual screening, and experimental validation. 
  • Discovery of novel FFA4 (GPR120) receptor agonists with β-arrestin2-biased characteristics. 
  • Discovery of novel bacterial elongation condensing enzyme inhibitors by virtual screening. 
  • Discovery of novel ligands for mouse olfactory receptor MOR42-3 using an in silico screening approach and in vitro validation. 
  • Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors. 
  • Drug-target identification in Drosophila cells: combining high-throughout RNAi and small-molecule screens. 
  • Effect of neuronol on lifespan and development of spontaneous tumors in SAMP-1 mice with genetically accelerated aging. 
  • Effects of a novel Mac-1 inhibitor, NPC 15669, on hemostatic parameters during preconditioned myocardial infarction. 
  • Effects of novel ethacrynic acid derivatives on human trabecular meshwork cell shape, actin cytoskeletal organization, and transcellular fluid flow. 
  • Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice. 
  • Electrical alternans and hemodynamics in the anesthetized guinea pig can discriminate the cardiac safety of antidepressants. 
  • Emerging therapeutic approaches in the management of retinal angiogenesis and edema. 
  • Endoglin Targeting: Lessons Learned and Questions That Remain. 
  • Evaluation of 5-(2-(4-pyridinyl)vinyl)-6-chloro-3-(1-methyl-2-(S)-pyrrolidinylmethoxy)pyridine and its analogues as PET radioligands for imaging nicotinic acetylcholine receptors. 
  • Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro. 
  • Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. 
  • Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles. 
  • Extracorporeal shock wave lithotripsy: the use of chemical treatments for improved stone comminution. 
  • Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease. 
  • First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach. 
  • Fluorescent peptide displacement as a general assay for screening small molecule libraries against RNA. 
  • Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models. 
  • Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association. 
  • GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain. 
  • Genome-editing Technologies for Gene and Cell Therapy. 
  • Genomic RNA Elements Drive Phase Separation of the SARS-CoV-2 Nucleocapsid. 
  • HIV-Host Interactions: Implications for Vaccine Design. 
  • Healing of a free tracheal autograft is enhanced by topical vascular endothelial growth factor in an experimental rabbit model. 
  • High-Throughput Video Processing of Heart Rate Responses in Multiple Wild-type Embryonic Zebrafish per Imaging Field. 
  • High-throughput screening for modulators of cellular contractile force. 
  • Host-Directed Therapies for Tuberculosis. 
  • Human Vascular Microphysiological System for in vitro Drug Screening. 
  • Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma. 
  • Identification of an allosteric small-molecule inhibitor selective for the inducible form of heat shock protein 70. 
  • Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries. 
  • Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. 
  • Imidazo[4,5-d]thiazolo[5,4-b]pyridine based inhibitors of IKK2: synthesis, SAR, PK/PD and activity in a preclinical model of rheumatoid arthritis. 
  • Immunotherapy for gynaecological malignancies. 
  • Improvement in efficacy of corticosteroid therapy in an animal model of proliferative vitreoretinopathy by pretreatment. 
  • Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials. 
  • Improving the assessment of heart toxicity for all new drugs through translational regulatory science. 
  • In vitro evaluation of dimethane sulfonate analogues with potential alkylating activity and selective renal cell carcinoma cytotoxicity. 
  • In vitro versus in vivo correlations of chemosensitivity of human medulloblastoma. 
  • Influence of dimethylsulfoxide on RNA structure and ligand binding. 
  • Inhibiting glycogen synthase kinase-3 mitigates the hematopoietic acute radiation syndrome in mice. 
  • Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma. 
  • Inhibition of the transcriptional activator protein nuclear factor kappaB prevents hemodynamic instability associated with the whole-body inflammatory response syndrome. 
  • Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission. 
  • Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program. 
  • Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling. 
  • Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. 
  • Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. 
  • Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program. 
  • Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. 
  • Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program. 
  • Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. 
  • Initial testing of cisplatin by the pediatric preclinical testing program. 
  • Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. 
  • Initial testing of topotecan by the pediatric preclinical testing program. 
  • Integration of molecular diagnostics with therapeutics: implications for drug discovery and patient care. 
  • International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. 
  • Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. 
  • Intravesical ultrapotent vanilloid receptor agonists: acute effects on animal models of bladder irritation. 
  • Investigation of antiestrogenic properties of unleaded gasoline in female mice. 
  • Is There a Space-Based Technology Solution to Problems with Preclinical Drug Toxicity Testing? 
  • LFA-1 blockade induces effector and regulatory T-cell enrichment in lymph nodes and synergizes with CTLA-4Ig to inhibit effector function. 
  • Leukotriene C4 induces migration of human monocyte-derived dendritic cells without loss of immunostimulatory function. 
  • Liver-stage malaria parasites vulnerable to diverse chemical scaffolds. 
  • Low molecular weight catalytic metalloporphyrin antioxidant AEOL 10150 protects lungs from fractionated radiation. 
  • Machine Learning Assisted Approach for Finding Novel High Activity Agonists of Human Ectopic Olfactory Receptors. 
  • Measurement of fat/water ratios in rat liver using 3D three-point dixon MRI. 
  • Mechanism-based discovery as an approach to identify the next generation of estrogen receptor modulators. 
  • Medicine. A portfolio model of drug development for tuberculosis. 
  • Medicine. The need for a global HIV vaccine enterprise. 
  • Mesenchymal Stem Cell Therapy in Stroke: A Systematic Review of Literature in Pre-Clinical and Clinical Research. 
  • Metabolomic Profiling to Identify Molecular Biomarkers of Cellular Response to Methotrexate In Vitro. 
  • Metformin prevents tobacco carcinogen--induced lung tumorigenesis. 
  • Methylglyoxal augments intracellular oxidative stress in human aortic endothelial cells. 
  • Mitogen-activated protein kinases in heart development and diseases. 
  • Molecular characterization of the pediatric preclinical testing panel. 
  • Molecular imaging of alkylguanine-DNA alkyltransferase: further evaluation of radioiodinated derivatives of O6-benzylguanine. 
  • Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. 
  • Monosodium urate crystal induced macrophage inflammation is attenuated by chondroitin sulphate: pre-clinical model for gout prophylaxis? 
  • N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. 
  • Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference. 
  • Non-invasive monitoring of intra-tumor drug concentration and therapeutic response using optical spectroscopy. 
  • Novel Manganese-Porphyrin Superoxide Dismutase-Mimetic Widens the Therapeutic Margin in a Preclinical Head and Neck Cancer Model. 
  • Novel medication targets for the treatment of alcoholism: preclinical studies. 
  • O6-3-[131I]iodobenzylguanine: improved synthesis and further evaluation of a potential agent for imaging of alkylguanine-DNA alkyltransferase. 
  • Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis. 
  • On the estimation of total variability in assay validation. 
  • Optical coding of mammalian cells using semiconductor quantum dots. 
  • Oral activated charcoal prevents experimental cerebral malaria in mice and in a randomized controlled clinical trial in man did not interfere with the pharmacokinetics of parenteral artesunate. 
  • PTEN reconstitution alters glioma responses to c-Met pathway inhibition. 
  • Panobinostat for the management of multiple myeloma. 
  • Partial liquid ventilation influences pulmonary histopathology in an animal model of acute lung injury. 
  • Partial liquid ventilation reduces pulmonary neutrophil accumulation in an experimental model of systemic endotoxemia and acute lung injury. 
  • Pathophysiological significance of c-jun N-terminal kinase in acetaminophen hepatotoxicity. 
  • Pediatric cardiovascular safety: challenges in drug and device development and clinical application. 
  • Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout. 
  • Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia. 
  • Pharmacomechanical thrombolysis of experimental pulmonary emboli. Rapid low-dose intraembolic therapy. 
  • Physiology and metabolism of tissue-engineered skeletal muscle. 
  • Pipeline pharmacogenetics: a novel approach to integrating pharmaco-genetics into drug development. 
  • Practical outcomes of applying ensemble machine learning classifiers to High-Throughput Screening (HTS) data analysis and screening. 
  • Prasugrel. 
  • Preclinical Alzheimer Disease Drug Development: Early Considerations Based on Phase 3 Clinical Trials. 
  • Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels. 
  • Preclinical Testing of a Novel Niclosamide Stearate Prodrug Therapeutic (NSPT) Shows Efficacy Against Osteosarcoma. 
  • Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain. 
  • Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia. 
  • Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. 
  • Preclinical toxicity evaluation of AAV for pain: evidence from human AAV studies and from the pharmacology of analgesic drugs. 
  • Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats. 
  • Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. 
  • Prenatal nicotine effects on memory in rats: pharmacological and behavioral challenges. 
  • Pretransplant Desensitization with Costimulation Blockade and Proteasome Inhibitor Reduces DSA and Delays Antibody-Mediated Rejection in Highly Sensitized Nonhuman Primate Kidney Transplant Recipients. 
  • Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse. 
  • Profiling heparin-chemokine interactions using synthetic tools. 
  • Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. 
  • Prospects for cellular immunotherapy for metastatic melanoma. 
  • Proteasome inhibitor attenuates skeletal muscle reperfusion injury by blocking the pathway of nuclear factor-kappaB activation. 
  • Psychedelic-inspired drug discovery using an engineered biosensor. 
  • Quantifying intrinsic specificity: a potential complement to affinity in drug screening. 
  • REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis. 
  • RTP family members induce functional expression of mammalian odorant receptors. 
  • Radioprotective effects of amifostine on acute and chronic esophageal injury in rodents. 
  • Rapid tissue prototyping with micro-organospheres. 
  • Reference compounds for alternative test methods to indicate developmental neurotoxicity (DNT) potential of chemicals: example lists and criteria for their selection and use. 
  • Replication-Competent Influenza B Reporter Viruses as Tools for Screening Antivirals and Antibodies. 
  • Reported lifetime aberrant drug-taking behaviors are predictive of current substance use and mental health problems in primary care patients. 
  • Repurposing cancer drugs identifies kenpaullone which ameliorates pathologic pain in preclinical models via normalization of inhibitory neurotransmission. 
  • Rigorous pre-clinical evaluation of topical microbicides to prevent transmission of human immunodeficiency virus. 
  • Rivaroxaban, an oral direct factor Xa inhibitor. 
  • Robotically handled whole-tissue culture system for the screening of oral drug formulations. 
  • SYK inhibitor entospletinib prevents ocular and skin GVHD in mice. 
  • Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. 
  • Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines. 
  • Stimulation of Respiratory Motor Output and Ventilation in a Murine Model of Pompe Disease by Ampakines. 
  • Synthesis and Biological Evaluation of Manassantin Analogues for Hypoxia-Inducible Factor 1α Inhibition. 
  • Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx). 
  • Taming Amphotericin B. 
  • Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. 
  • Taxis assays measure directional movement of mosquitoes to olfactory cues. 
  • Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. 
  • Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. 
  • Tezosentan normalizes hepatomesenteric perfusion in a porcine model of cardiac tamponade. 
  • The BET-Bromodomain Inhibitor JQ1 Reduces Inflammation and Tau Phosphorylation at Ser396 in the Brain of the 3xTg Model of Alzheimer's Disease. 
  • The Regulation of Proresolving Lipid Mediator Profiles in Baboon Pneumonia by Inhaled Carbon Monoxide. 
  • The SATE pronucleotide approach applied to acyclovir: part II. Effects of bis(SATE)phosphotriester derivatives of acyclovir on duck hepatitis B virus replication in vitro and in vivo. 
  • The antifungal pipeline: a reality check. 
  • The azaspirane SKF 105685 ameliorates renal allograft rejection in rats. 
  • The effect of berotec (Th 1165a) on spontaneous and induced uterine activity in the pregnant baboon. 
  • The effect of levofloxacin on the lung microbiota of laboratory rats. 
  • The effects of N(omega)-propyl-L-arginine on reperfusion injury of skeletal muscle. 
  • The future of preclinical animal models in pharmaceutical discovery and development: a need to bring in cerebro to the in vivo discussions. 
  • The price of innovation: new estimates of drug development costs. 
  • The use of nonhuman primate models in HIV vaccine development. 
  • The β-adrenoceptor agonist isoproterenol rescues acetaminophen-injured livers through increasing progenitor numbers by Wnt in mice. 
  • Timing of valproic acid in acute lung injury: prevention is the best therapy? 
  • Tissue-engineered blood vessels as promising tools for testing drug toxicity. 
  • Tolevamer, an orally administered, toxin-binding polymer for Clostridium difficile-associated diarrhea. 
  • Treatment of human glioma and medulloblastoma tumor lines in athymic mice with diaziquone and diaziquone-based drug combinations. 
  • Treatment of xerophthalmia with retinol, tretinoin, and etretinate. 
  • Use of etoposide in combination with cyclosporine for purging multidrug resistant leukemic cells from bone marrow in a mouse model. 
  • Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction. 
  • VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer. 
  • White paper on microbial anti-cancer therapy and prevention. 
  • Wnt Signaling and Drug Resistance in Cancer. 
  • X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. 
  • Zebrafish assessment of cognitive improvement and anxiolysis: filling the gap between in vitro and rodent models for drug development. 
  • [LMP-420, a new therapeutic approach for cerebral malaria?]. 
  • gamma-Aminobutyric acid(A) neurotransmission and cerebral ischemia. 
• 

  Keywords of People

  • Berger, Miles, Associate Professor of Anesthesiology, Duke Science & Society
  • Bradford, Daniel William, Professor of Psychiatry and Behavioral Sciences, Psychiatry, Child & Family Mental Health & Community Psychiatry
  • Chitneni, Satish K., Associate Professor in Radiology, Radiology
  • Cianciolo, George James, Associate Professor Emeritus of Pathology, Pathology
  • Johnson, G. Allan, Charles E. Putman University Distinguished Professor of Radiology, Biomedical Engineering
  • Lee, Walter T, Professor of Head and Neck Surgery & Communication Sciences, Radiation Oncology
  • McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Cell Biology
  • Nielsen, Karen Cristina, Associate Professor of Anesthesiology, Anesthesiology, Ambulatory
  • Palmer, Gregory M., Associate Professor of Radiation Oncology, Radiation Oncology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering